The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy
Open Access
- 20 December 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 22 (3), 521-529
- https://doi.org/10.1038/sj.leu.2405066
Abstract
Acute myeloid leukemia (AML) in Down syndrome (DS) children has several unique features including a predominance of the acute megakaryocytic leukemia (AMkL) phenotype, higher event-free survivals compared to non-DS children using cytosine arabinoside (ara-C)/anthracycline-based protocols and a uniform presence of somatic mutations in the X-linked transcription factor gene, GATA1. Several chromosome 21-localized transcription factor oncogenes including ETS2 may contribute to the unique features of DS AMkL. ETS2 transcripts measured by real-time RT–PCR were 1.8- and 4.1-fold, respectively, higher in DS and non-DS megakaryoblasts than those in non-DS myeloblasts. In a doxycycline-inducible erythroleukemia cell line, K562pTet-on/ETS2, induction of ETS2 resulted in an erythroid to megakaryocytic phenotypic switch independent of GATA1 levels. Microarray analysis of doxycycline-induced and doxycycline-uninduced cells revealed an upregulation by ETS2 of cytokines (for example, interleukin 1 and CSF2) and transcription factors (for example, TAL1), which are key regulators of megakaryocytic differentiation. In the K562pTet-on/ETS2 cells, ETS2 induction conferred differences in sensitivities to ara-C and daunorubicin, depending on GATA1 levels. These results suggest that ETS2 expression is linked to the biology of AMkL in both DS and non-DS children, and that ETS2 acts by regulating expression of hematopoietic lineage and transcription factor genes involved in erythropoiesis and megakaryopoiesis, and in chemotherapy sensitivities.Keywords
This publication has 56 references indexed in Scilit:
- Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemiaBlood, 2006
- Acute leukaemia in children with Down syndrome: a population‐based Nordic studyBritish Journal of Haematology, 2005
- Natural history of GATA1 mutations in Down syndromeBlood, 2004
- Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Cancer Group Study 2891Journal of Clinical Oncology, 2003
- RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiationBlood, 2003
- Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53Published by Elsevier BV ,2001
- ETS2 function is required to maintain the transformed state of human prostate cancer cellsOncogene, 1998
- Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancerThe Prostate, 1997
- Lethal β-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLFNature, 1995
- Rapid and transient expression of Ets2 in mature macrophages following stimulation with cMGF, LPS, and PKC activators.Genes & Development, 1990